TY - JOUR TI - Metformin and intravenous contrast when time not help, A retrospective study at King Abdulaziz University Hospital, Jeddah, Saudi Arabia A1 - Alqarni, Dalya A2 - Alshehri, Asma A3 - Aldehasi, Raghad A4 - Al-Sayegh, Lujain A5 - Binrahma, Dania A6 - AlShoaibi, Naeem JF - International Journal of Medicine in Developing Countries JO - IJMDC SN - 1658-7820 VL - 3 IS - 1 SP - 26 EP - 29 Y1 - 2019 AB - Background: Metformin is a common drug used for antihyperglycemic therapy in type 2 diabetes. Additionally, intravenous (IV) contrast may be administered when using the various imaging techniques to enhance the visualization of body structures, and deterioration of renal function and lactic acidosis - contrast-induced nephropathy (CIN) - may occasionally happen. The purpose of this research was to assess the current guideline of withholding metformin therapy in patients undergoing contrast-enhanced procedures in both the emergency and inpatient settings.Methodology: A retrospective study was conducted for all patients who were on metformin and underwent a contrast-enhanced imaging procedure (requiring IV contrast) between January and June 2016 at King Abdulaziz University Hospital in Jeddah, Saudi Arabia.Results: This study involved 107 patients on metformin who received a contrast-enhanced imaging procedure. Out of 107 patients, 26 were admitted through the ER. Independent t-tests were performed to compare GFR and creatinine, before and after the procedure in both, ER and ward patients; they all had non-significant associations.Conclusion:In this study none of the ER patients stopped their metformin before they were administered IV contrast. PB - https://www.ijmdc.com DO - 10.24911/IJMDC.51-1543999258 UR - https://www.ijmdc.com/?mno=20293 ER -